Skip to content

ImmunityBio

US · IBRX #1397 by market cap Listed 1970
6.02 -0.55 -8.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Valuation each multiple against its own 5-year range

P/B ratio -5.58 In line with history 41st percentile
5-year average -6.15
P/E ratio -5.68 Cheap vs history 28th percentile
5-year average -5.48 · forward -15.71
P/S ratio 35.08 Cheap vs history 9th percentile
5-year average 2,386.29 · forward 21.42 · #246 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
ImmunityBio (IBRX) 6.40B -5.68 -5.58 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value8.95 Economic moatNone UncertaintyVery High

Trading 48.6% below Morningstar's fair value estimate.

Fair value

ImmunityBio Inc earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 33% discount to our quantitative fair value estimate of $8.95 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's liquidity increases our fair value estimate. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. Reflecting the firm's liquidity is its median trading volume over the past 60 days, which ranks in the top 10% compared with global peers. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be cheap.

On a different note, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of -11.5%, a core component of valuation, falls in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:59:40 · For reference only, not investment advice and not tailored to your situation.

ImmunityBio discussion 0 comments

Add a comment